Radiopharm's Brain Cancer Imaging Agent Shows 92% Success in Phase 2 Trial

Radiopharm Theranostics (RADX) reports promising interim results for RAD 101, a novel brain metastases imaging agent, with 92% accuracy matching MRI scans in clinical trial.